Join us for our Customer Intelligence Webinar on Oct 26, 2021 Register Now
Intellizence
  • Platform
    • NEWS SIGNALS
      • Company Intelligence
      • Industry Intelligence
    • DATASETS
      • Merger & Acquisition
      • Startup Funding
      • Business Expansion
      • Layoff
      • Major Hiring
      • CXO Appointment & Changes
      • Data & Security Breaches
  • Solutions
    • Customer Intelligence
    • Sales Intelligence
    • Market Intelligence
    • Risk Intelligence
    • Competitive Intelligence
  • Insights
    • Companies
      • Companies Explorer
      • Data & Intelligence
      • Top Companies
      • Layoffs
      • Mergers & Acquisitions
      • CXO – Changes
    • Research & Insights
      • Merger & Acquisition
      • Startup Funding
      • Product Launch
      • Layoff/Downsizing
      • Bankruptcy
      • Alliance & Partnership
      • Hiring
      • IPO
      • Data Security Breach
      • ESG & Diversity
      • Business Expansion
      • Executive Appointments
    • Trends
      • Coronavirus
      • Emerging Technologies
      • Macro Trends
      • Generative AI
  • Customers
  • Company
    • About Intellizence
    • Leadership Team
    • Advisory Board
    • Awards & Recognition
    • We Are Hiring!
    • In The News
    • Press Releases
  • Login
  • Start a Free Trial
Intellizence
  • Platform
    • NEWS SIGNALS
      • Company Intelligence
      • Industry Intelligence
    • DATASETS
      • Merger & Acquisition
      • Startup Funding
      • Business Expansion
      • Layoff
      • Major Hiring
      • CXO Appointment & Changes
      • Data & Security Breaches
  • Solutions
    • Customer Intelligence
    • Sales Intelligence
    • Market Intelligence
    • Risk Intelligence
    • Competitive Intelligence
  • Insights
    • Companies
      • Companies Explorer
      • Data & Intelligence
      • Top Companies
      • Layoffs
      • Mergers & Acquisitions
      • CXO – Changes
    • Research & Insights
      • Merger & Acquisition
      • Startup Funding
      • Product Launch
      • Layoff/Downsizing
      • Bankruptcy
      • Alliance & Partnership
      • Hiring
      • IPO
      • Data Security Breach
      • ESG & Diversity
      • Business Expansion
      • Executive Appointments
    • Trends
      • Coronavirus
      • Emerging Technologies
      • Macro Trends
      • Generative AI
  • Customers
  • Company
    • About Intellizence
    • Leadership Team
    • Advisory Board
    • Awards & Recognition
    • We Are Hiring!
    • In The News
    • Press Releases
  • Login
  • Start a Free Trial
Nov 09

Pfizer-BioNTech COVID-19 Vaccine Candidate 90% Effective in Phase 3 Trial

  • November 9, 2020
  • coronavirus, Coronavirus, Insights

Pfizer and BioNTech SE, have announced their mRNA-based vaccine candidate, BNT162b2, was more than 90 percent effective in preventing Covid-19 infections. One of the top 9 companies leading the COVID-19 vaccine race, Pfizer & BioNTech are closer to providing people around the world with the much-needed breakthrough to end this global health crisis.

Protection in patients was achieved seven days after the second of two doses, and 28 days after the first, according to preliminary findings.

The first interim efficacy analysis was conducted by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study. The vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without prior evidence of SARS-CoV-2 infection.

The Phase 3 clinical trial that started on July 27 has around 43,538 participants to date, out of which 38,955 have received a second dose of the vaccine candidate as of November 8, 2020.

Based on the preliminary results the companies will seek an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) if further research shows the shot is safe, which is currently expected to occur in the third week of November. 

“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO.

Based on supply projections, the companies said they expect to globally produce up to 50 million vaccine doses in 2020, and up to 1.3 billion doses in 2021.

Intellizence is an award-winning AI platform for Company Intelligence & Industry Intelligence. We can help you to monitor signals like product launches in your interested companies as well as emerging innovation trends like COVID-19 vaccine research & development updates.

Please follow us on LinkedIn and Twitter to get regular update 

Interested in Intellizence? 

REQUEST A DEMO

  • Twitter
  • LinkedIn
  • E-Mail

Get Actionable Intelligence about your Target Companies & Industry Trends

chrom Identify Emerging Opportunities & Risks

chrom Make Better Decisions

chrom Grow & Stay Ahead

Start a Free Trial Schedule a Demo

Company

  • Team
  • Advisory Board
  • In the News
  • We are Hiring!

Resources

  • Blog
  • Guides
  • API Document
  • Intellizence Company Signals
  • Companies Explorer
  • Webinars
  • Newsletter
  • Case Studies

Others

  • Privacy Policy
  • Terms of Service

Contact Info

Intellizence

Address: 55 York Street, Suite 401,
Toronto ON M5J 1R7
Phone: +1 (416) 887 4880
Email: info@intellizence.com

Copyrights © 2023 All Rights Reserved by Intellizence, Inc.

Share

Blogger
Delicious
Digg
Email
Facebook
Facebook messenger
Flipboard
Google
Hacker News
Line
LinkedIn
Mastodon
Mix
Odnoklassniki
PDF
Pinterest
Pocket
Print
Reddit
Renren
Short link
SMS
Skype
Telegram
Tumblr
Twitter
VKontakte
wechat
Weibo
WhatsApp
X
Xing
Yahoo! Mail

Copy short link

Copy link